PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2124009
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2124009
According to Mordor Intelligence, the chitosan market size is estimated at USD 6.30 billion in 2026, and is expected to reach USD 11.30 billion by 2031, at a CAGR of 12.38% during the forecast period (2026-2031).

This report is Segmented by Source (Shrimps, Crabs, and More), Grade (Industrial Grade, Food Grade, and More), Form (Powder, Flake, and More), Application (Water Treatment, Cosmetics and Personal Care, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Research Report Offers the Value (in USD) for the Above Segments.
Utilities in the European Union must now install quaternary treatment that targets micropollutants, and chitosan simultaneously coagulates colloids and adsorbs trace organics, reducing alum use by up to 30%. Industrial sites in the United States face stricter 40 CFR Part 125 limits for heavy metals, and chitosan derivatives remove 93-99% of iron, copper and zinc without hazardous sludge. China has cut total chromium limits for electroplating effluent to 0.5 mg L-1, prompting early adoption of chitosan flocculants in Zhejiang and Guangdong. These converging regulations enlarge the addressable market for high-deacetylation chitosan grades that assure both performance and biodegradability.
Brand owners pursuing plastic-free packaging and compostable agriculture inputs are specifying chitosan films that degrade 80-90% within 60 days under industrial composting, far faster than polyethylene. The Single-Use Plastics Directive in Europe curbs oxo-degradable polymers, directing formulators toward chitosan seed coatings and controlled-release fertilizers that leave no persistent residue. Hair-care brands are reformulating gels with quaternized chitosan that delivers hold without microplastics, leveraging marine-origin storytelling to command premium shelf pricing. These preferences move the global chitosan market beyond compliance, turning biodegradability into a marketing advantage.
Residual proteins in lower-grade crustacean chitosan can trigger IgE reactions in shellfish-sensitized individuals, leading the European Food Safety Authority to delay opinions on direct food contact and forcing cosmetic brands to label shellfish origin. Fungal and insect chitosan could bypass allergen labeling, but clinical safety dossiers remain incomplete, holding back full-scale commercialization. Until risk assessments conclude, formulators in mass-market foods and cosmetics will limit chitosan inclusion or invest in higher-purity grades, tempering near-term volume growth.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Shrimp shells yielded 45.55% of global chitosan market output in 2025, supported by established logistics in Thailand, Vietnam and India that channel 1.5 million t of shell waste into dedicated deacetylation lines. Crabs are forecast to lead growth at a 13.25% CAGR as processors in Alaska and Northern Europe consolidate shell recovery, boosting deacetylation yields and lowering unit costs. Insect exoskeletons and fungal biomass are emerging feedstocks with vegan, Halal and Kosher positioning, yet extraction costs remain 20-30% higher owing to immature infrastructure. Seasonal variability still influences the global chitosan market, as climate anomalies shrink shrimp harvests in El Nino years, prompting processors to hedge supply with mixed crustacean and fungal inputs. Although squid-derived chitosan remains a niche, its clarity and low viscosity command premium pricing in high-end cosmetics, revealing the diversification potential within marine feedstocks.
Crab-based capacity expansions in Norway and Canada are backed by grants that subsidize cold-water fishery waste valorization, reinforcing supply security for European buyers seeking traceability under the EU Green Deal. Asian government incentives for insect farming on food waste are likewise nurturing pilot-scale black soldier fly chitosan plants, opening a circular-economy storyline. While insect chitosan currently represents less than 2% of global chitosan market volume, favorable life-cycle assessments could accelerate its share once purification costs fall. Overall, feedstock diversification limits raw-material risk and supports stable pricing in a market vulnerable to aquaculture disease outbreaks.
Industrial-grade material commanded 45.53% of the global chitosan market size in 2025, filling water-treatment and textile niches where 75-85% deacetylation suffices. Pharmaceutical and biomedical grades, however, will outpace commodity specifications at 12.85% CAGR through 2031 as clinical evidence spreads and military procurement of hemostatic dressings rises. The degree of deacetylation, endotoxin burden and molecular-weight range define price tiers, with Good Manufacturing Practice batches retailing at 3-10 times industrial equivalents.
Drug-carrier patents covering chitosan-collagen composites and nano-gel matrices strengthen price resilience, while oligopolistic supply from Primex, Heppe Medical Chitosan and a few Chinese DMF holders preserves market discipline. Food-grade chitosan, positioned between industrial and medical benchmarks, benefits from Generally Recognized as Safe status in the United States yet awaits full clearance in Europe. As a result, the grade hierarchy widens, segmenting buyers by regulatory exposure and margin appetite rather than sheer volume requirements.
Europe will post the strongest 14.51% CAGR through 2031, propelled by quaternary wastewater mandates and the biostimulant classification that simplifies chitosan deployment in farming. Germany funds municipal trials that replace polyacrylamide with chitosan, and Spain deploys chitosan sprays in viticulture to reduce synthetic fungicide load. United Kingdom trauma centers have standardized chitosan dressings, boosting hospital demand and reinforcing the region's leadership in medical applications.
North America captured 25.13% of global chitosan market share in 2025, anchored by EPA pretreatment standards and early battlefield use of chitosan hemostats. Growth moderates as water-treatment installations mature, yet pharmaceutical prospects remain attractive as inhaled-drug-grade chitosan wins its first USP monograph. Canada's cold-water crab fisheries provide low-contaminant shells, supporting premium pharmaceutical supply chains and reinforcing regional competitiveness.
Asia-Pacific supplies most feedstock, processing about 2 million t of shell waste annually in Thailand, Vietnam and China. Domestic chitosan uptake is uneven; China tightened chromium discharge limits, catalyzing localized adoption, but enforcement gaps restrain nationwide penetration. Japan specializes in cosmetic-grade oligosaccharides with proprietary hydrolysis technology, while India's aquaculture hubs expand industrial-grade output for global export. Emerging markets in the Middle East test chitosan as a pretreatment in desalination, and South America inches forward with Brazil deploying chitosan bio-pesticides in organic soy farming amid tariff and infrastructure headwinds.